Search Results

Displaying: 25 / 100 / 200 results

Ordered by: Date (newest first) / Date (oldest first)

1234lastnext

Bespoke or bodged

30 April 2013 In the Pipeline

A can-do attitude and some lateral thinking can save time and money when it comes to exotic apparatus, says Derek Lowe

From lab to leader

2 April 2013 In the Pipeline

Derek Lowe asks (with some trepidation): do drug companies need scientists at the top?

New antibiotics: what's the hold up?

6 March 2013 In the Pipeline

It’s more a research problem, than a commercial one, says Derek Lowe

Name reactions: how does the label stick?

25 January 2013 In the Pipeline

Derek Lowe investigates the long running tradition of naming reactions after their inventors

Fear of the unknown

2 January 2013 In the Pipeline

How do you reconcile the need for personal safety with unfamiliar compounds, asks Derek Lowe

Full disclosure?

27 November 2012 In the Pipeline

The pharma industry should be more open with its trial data, says Derek Lowe

High finance meets big pharma?

31 October 2012 In the Pipeline

Derek Lowe examines an alternative funding model for pharmaceutical research

Under pressure

26 September 2012 In the Pipeline

There might be a better way to interview new starters, suggests Derek Lowe

Light in the lab

4 September 2012 In the Pipeline

Derek Lowe asks: Why don’t we use photochemistry more often?

Screen shots

26 July 2012 In the Pipeline

Derek Lowe makes the case against using 'frequent hitters' in your assays

A personnel question

21 June 2012 In the Pipeline

Derek Lowe would back a team of risk takers if he had to

Column: In the pipeline

28 March 2012 In the Pipeline

How long is 'too long' in the drug discovery game? Derek Lowe considers the effects of life in the lab

Column: In the pipeline

23 February 2012 In the Pipeline

Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love

Column: In the pipeline

27 January 2012 In the Pipeline

Derek Lowe wonders what the lab lingua franca might be in the years to come

Column: In the pipeline

22 December 2011 In the Pipeline

Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about

Column: In the pipeline

28 November 2011 In the Pipeline

Derek Lowes considers the perfect lab environment

Column: In the pipeline

26 October 2011 In the Pipeline

Derek Lowe discusses the compounds you can buy but won't see anywhere in the literature

Column: In the pipeline

29 September 2011 In the Pipeline

You have to make space for good sense when thinking about safety, argues Derek Lowe

Column: In the pipeline

26 August 2011 In the Pipeline

Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal

Column: In the pipeline

28 July 2011 In the Pipeline

Derek Lowe highlights the less visible pitfalls on the road to a new drug

Column: In the pipeline

30 June 2011 In the Pipeline

The financial markets can be a rollercoaster ride, writes Derek Lowe, so should chemists working in industry worry about the company share price?

Column: In the pipeline

31 May 2011 In the Pipeline

To the unfamiliar, chemists might all look the same. But some common categories are easy to identify, explains Derek Lowe

Column: In the pipeline

28 April 2011 In the Pipeline

The map of scientific disciplines is growing ever more complex. Derek Lowe surveys the country

Column: In the pipeline

30 March 2011 In the Pipeline

'Natural products are back!' is a headline Derek Lowe has seen several times before

Column: In the pipeline

24 February 2011 In the Pipeline

Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
1234lastnext

Selected Filters

Filter Results

Article type

Author

Date range

Custom date range

Date from:

Date to: